Treatment of diabetes mellitus by taking insulin PEGylation derivative as active component

Abstract

The invention discloses treatment of diabetes mellitus by taking insulin PEGylation derivative as an active component, which is characterized in that a drug delivery mode of single injection can be changed, and the patient tolerance is increased. After PEGylation of insulin, the renal clearance is reduced, the enzymolysis speed is reduced, the retention time of insulin in human body is increased, the drug delivery cycle is prolonged, and the treatment cost is reduced.

Description

technical field [0001] The present invention relates to treating diabetes with insulin PEGylated derivatives as active ingredients. Background technique [0002] On August 5, 2011, "Life Times" reported that the incidence of diabetes in China was 6.7%, higher than the world average of 6.4%. Moreover, the high-risk population of diabetes in China is also expanding, with about 150 million people. The rejuvenation of diabetic patients is also a harsh reality that our country must face. Type 1 diabetes requiring insulin therapy accounts for about 10% of diabetic patients. Many people with type 2 diabetes also need insulin injections for treatment. Most of them need insulin injection three times a day, and it is long-term, which brings great pain and treatment cost to patients. [0003] Domestically marketed insulins include synthetic insulin, insulin extracted from animal viscera, neutral insulin, insulin glargine, insulin aspart, insulin glulisine, insulin detemir, recombin...

AI Technical Summary

Problems solved by technology

Most of them need insulin injection three times a day, and it is long-term, which brings great pain and treatment cost to patients